S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.10
+360.20
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.10
+62.50
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
AKTX · Akari Therapeutics plc ADS
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
Akari Therapeutics PLC (AKTX)
NASDAQ NMS - GLOBAL MARKET
Biotechnology
$9.57
+0.40
(+4.36%)
● At close: October 21 at 4:00:00 PM EDT
DAY'S RANGE
$9.57
$9.57
$9.57
52-WEEK RANGE
$9.57
$3.02
$33.60
What's happening
- AKTX is up 4.36% today, trading at $9.57. — Live quote
- Volume today (241) is well below its 3-month average of 69,940. (Finnhub fundamentals)
- Reports earnings on 2026-11-11, 20 days away. (Finnhub earnings calendar)
- Last quarter's EPS missed estimates: $-2.68 actual vs. $-1.31 estimated (-105.3%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 3
Buy 6
Hold 1
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (10 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
AKTX
-14.45%
vs S&P 500
-26.85%
1-YEAR RETURN
AKTX
-69.09%
vs S&P 500
-84.46%
6-MONTH RETURN
AKTX
+114.53%
3-MONTH RETURN
AKTX
-7.22%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-2.68
Est. $-1.31
MISS -105.3%
2026-04-26 (Q1 2026)
$-1.57
Est. $-1.40
MISS -11.8%
2026-01-26 (Q4 2025)
$0.00
Est. $-1.53
BEAT +100.0%
2025-10-26 (Q3 2025)
$0.00
Est. $-3.13
BEAT +100.0%
Valuation Measures & Ratios
Enterprise Value4$9.3M
Forward P/E5—
PEG Ratio6-0.06
Price / Sales (TTM1)—
Price / Book70.98
EV4 / Revenue—
EV4 / EBITDA—
Profit Margin—
Operating Margin—
Return on Equity (ROE8)-147.45%
Return on Assets (ROA9)-74.70%
Avg Volume (3M)69,940
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short14,529
Change from Prior Settlement+34.99%
% of Float—
Days to Cover (Short Ratio)1.00
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Latest SEC filing is Form 4, filed 2026-10-16; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Trailing 52-week price return is -69.1%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on AKTX
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Operating income | -$4.6M | -$15.8M | -$7.4M | -$3.1M | -$3.5M | -$2.9M | -$7.4M | -$6.0M |
| Net income | -$4.8M | -$14.5M | -$6.4M | -$1.9M | -$3.7M | -$2.9M | -$7.6M | -$5.6M |
| EPS (diluted) | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| EPS (basic) | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $38.6M | $33.9M | $47.9M | $45.4M | $50.9M | $51.0M | $50.6M | $2.7M |
| Total liabilities | $20.0M | $19.5M | $19.6M | $22.7M | $25.3M | $29.2M | $28.3M | — |
| Stockholders' equity | $18.6M | $14.4M | $28.3M | $22.7M | $25.6M | $21.7M | $22.2M | -$6.7M |
| Total current assets | $8.3M | $3.6M | $5.5M | $2.9M | $3.3M | $3.3M | $3.0M | $2.7M |
| Total current liabilities | $13.9M | $13.4M | $12.4M | $15.6M | $17.1M | $20.9M | $19.9M | $9.4M |
| Cash & equivalents | $7.7M | $2.8M | $5.2M | — | $2.7M | $2.6M | $0 | $2.2M |
| Other current assets | $38.0K | $30.0K | $14.0K | $53.0K | $83.0K | $80.0K | $201.0K | $92.0K |
| Property, plant & equipment | — | — | — | — | — | — | — | — |
| Goodwill | — | — | $8.4M | $8.4M | $8.4M | $8.4M | $8.4M | — |
| Intangible assets | — | — | — | — | — | — | — | — |
| Accounts payable | $9.4M | $8.6M | $8.8M | $10.8M | $11.6M | $13.1M | $12.4M | $4.8M |
| Accrued liabilities | $3.5M | $3.3M | $2.3M | $1.6M | $2.5M | $3.5M | $3.1M | $2.6M |
| Short-term debt | — | — | — | — | — | — | — | $200.0K |
| Other current liabilities | $212.0K | $697.0K | $424.0K | $481.0K | $650.0K | $484.0K | $94.0K | $316.0K |
| Other non-current liabilities | — | — | $31.0K | $69.0K | $128.0K | $266.0K | $383.0K | — |
| Common stock & paid-in capital | $1.0K | — | — | $6.5M | $6.5M | $5.8M | $5.3M | $2.4M |
| Retained earnings | -$283.8M | -$279.0M | -$264.6M | -$259.3M | -$252.9M | -$251.0M | -$247.3M | -$243.5M |
| Accumulated other comprehensive income (loss) | -$695.0K | -$768.0K | -$782.0K | -$1.1M | -$1.1M | -$773.0K | -$738.0K | -$926.0K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$3.1M | -$2.5M | -$3.0M | -$2.1M | -$3.3M | -$2.1M | -$2.1M | -$1.5M |
| Investing cash flow | — | — | — | — | — | — | $382.0K | — |
| Financing cash flow | $8.0M | $53.0K | $5.8M | $1.9M | $3.4M | $2.1M | $2.2M | -$443.0K |
| Capital expenditures | — | — | — | — | — | — | — | — |
| Depreciation & amortization | — | — | — | — | — | — | $1.0K | $0 |
| Share-based compensation | $711.0K | $305.0K | $471.0K | $685.0K | $719.0K | $1.0M | $1.3M | $248.0K |
| Deferred income taxes | $0 | -$859.0K | -$1.1M | — | — | — | — | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '15 |
|---|---|---|---|---|---|
| Operating income | -$17.3M | -$21.6M | -$16.8M | -$23.1M | -$30.6M |
| Net income | -$17.3M | -$19.8M | -$10.0M | -$17.7M | -$45.3M |
| EPS (diluted) | $0.00 | $0.00 | $0.00 | $0.00 | — |
| EPS (basic) | $0.00 | $0.00 | $0.00 | $0.00 | — |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $47.9M | $50.6M | $4.4M | $13.8M | — |
| Total liabilities | $19.6M | $28.3M | $4.6M | $12.0M | — |
| Stockholders' equity | $28.3M | $22.2M | -$229.0K | $1.8M | $5.6M |
| Total current assets | $5.5M | $3.0M | $4.3M | $13.8M | — |
| Total current liabilities | $12.4M | $19.9M | $4.6M | — | — |
| Cash & equivalents | $0 | $0 | $3.8M | $13.2M | — |
| Other current assets | $14.0K | $201.0K | $197.0K | $100.0K | — |
| Property, plant & equipment | — | — | — | — | — |
| Goodwill | $8.4M | $8.4M | — | — | — |
| Intangible assets | — | — | $14.0K | $17.0K | — |
| Accounts payable | $8.8M | $12.4M | $1.7M | $947.0K | — |
| Accrued liabilities | $2.3M | $3.1M | $1.6M | $3.1M | — |
| Other current liabilities | $424.0K | $94.0K | $94.0K | $94.0K | — |
| Other non-current liabilities | $31.0K | $383.0K | — | — | — |
| Common stock & paid-in capital | — | $5.3M | $1.3M | $745.0K | — |
| Retained earnings | -$264.6M | -$247.3M | -$227.5M | -$217.5M | — |
| Accumulated other comprehensive income (loss) | -$782.0K | -$738.0K | -$1.0M | -$771.0K | — |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '15 |
|---|---|---|---|---|---|
| Operating cash flow | -$10.6M | -$12.6M | -$16.4M | -$21.5M | -$5.0M |
| Investing cash flow | — | $382.0K | — | — | $1.4M |
| Financing cash flow | $13.2M | $11.0M | $7.0M | $25.3M | $69.0M |
| Free cash flow | — | — | — | — | -$5.0M |
| Capital expenditures | — | — | — | — | $10.6K |
| Depreciation & amortization | — | $14.0K | $4.0K | $4.0K | — |
| Share-based compensation | $2.9M | $2.2M | $1.1M | $735.0K | $1.0M |
| Deferred income taxes | -$1.1M | — | — | — | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding AKTX as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2025-06-23 to 2026-10-14
Recent transactions
- Most recent: Patel Sandip I (Director) — Option exercise of 3,866 shares on 2026-10-14.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)0 sh(0 txns)
Net Shares+0
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Patel Sandip I | Director | Option exercise | 2026-10-14 | 3,866 |
| Bazemore Robert B | Director | Option exercise | 2026-10-14 | 773 |
| Gaslightwala Abizer | CEO | Option exercise | 2026-10-14 | 19,333 |
| Prudo-Chlebosz Raymond | Director | Grant / award | 2026-10-05 | 3,240 |
| Huh Hoyoung | Director | Grant / award | 2026-10-05 | 6,160 |
| Patel Samir Rashmikant | Director | Grant / award | 2026-10-05 | 2,236 |
| Farag Kameel D. | Interim CFO | Grant / award | 2026-08-17 | 1,728 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-10-14 | Patel Sandip I | Director | Option exercise | 3,866 | $0.00 |
| 2026-10-14 | Patel Sandip I | Director | Option exercise | 6,186 | $0.00 |
| 2026-10-14 | Bazemore Robert B | Director | Option exercise | 773 | $0.00 |
| 2026-10-14 | Bazemore Robert B | Director | Option exercise | 3,093 | $0.00 |
| 2026-10-14 | Gaslightwala Abizer | CEO | Option exercise | 19,333 | $0.00 |
| 2026-10-14 | Gaslightwala Abizer | CEO | Option exercise | 7,733 | $0.00 |
| 2026-10-05 | Prudo-Chlebosz Raymond | Director | Grant / award | 3,240 | $7.90 |
| 2026-10-05 | Huh Hoyoung | Director | Grant / award | 6,160 | $7.90 |
| 2026-10-05 | Patel Sandip I | Director | Grant / award | 4,313 | $7.90 |
| 2026-10-05 | Bazemore Robert B | Director | Grant / award | 4,677 | $7.90 |
| 2026-10-05 | Patel Samir Rashmikant | Director | Grant / award | 2,236 | $7.90 |
| 2026-09-29 | Gaslightwala Abizer | CEO | Grant / award | 6,430 | $9.72 |
| 2026-08-18 | Prudo-Chlebosz Raymond | Director | Grant / award | 9,072 | $7.90 |
| 2026-08-18 | Huh Hoyoung | Director | Grant / award | 17,249 | $7.90 |
| 2026-08-18 | Patel Sandip I | Director | Grant / award | 12,100 | $7.90 |
| 2026-08-18 | Bazemore Robert B | Director | Grant / award | 13,100 | $7.90 |
| 2026-08-18 | Patel Samir Rashmikant | Director | Grant / award | 6,300 | $7.90 |
| 2026-08-17 | Farag Kameel D. | Interim CFO | Grant / award | 1,728 | $7.52 |
| 2026-07-16 | Farag Kameel D. | Interim CFO | Grant / award | 1,130 | $11.50 |
| 2026-07-07 | Patel Samir Rashmikant | Director | Option exercise | 1,209 | $8.00 |
| 2026-07-07 | Patel Samir Rashmikant | Director | Option exercise | 15,466 | $0.00 |
| 2026-07-07 | Patel Samir Rashmikant | Director | Option exercise | 5,799 | $0.00 |
| 2026-06-24 | Farag Kameel D. | Interim CFO | Grant / award | 1,248 | $10.02 |
| 2026-06-24 | Farag Kameel D. | Interim CFO | Grant / award | 1,395 | $9.32 |
| 2026-06-24 | Farag Kameel D. | Interim CFO | Grant / award | 1,570 | $8.28 |
| 2026-06-24 | Farag Kameel D. | Interim CFO | Grant / award | 2,539 | $5.12 |
| 2026-06-24 | Farag Kameel D. | Interim CFO | Grant / award | 3,725 | $3.49 |
| 2026-06-24 | Farag Kameel D. | Interim CFO | Grant / award | 7,353 | $3.74 |
| 2026-06-24 | Farag Kameel D. | Interim CFO | Grant / award | 1,000 | $13.00 |
| 2025-11-01 | Farag Kameel D. | Interim CFO | Grant / award | 32,000 | $0.75 |
| 2025-11-01 | Farag Kameel D. | Interim CFO | Grant / award | 26,619 | $0.75 |
| 2025-10-22 | Farag Kameel D. | Interim CFO | Grant / award | 6,277 | $0.74 |
| 2025-08-25 | Gaslightwala Abizer | CEO | Open market purchase | 3,000 | $0.90 |
| 2025-08-22 | Gaslightwala Abizer | CEO | Open market purchase | 8,000 | $0.93 |
| 2025-08-21 | Gaslightwala Abizer | CEO | Open market purchase | 10,000 | $0.94 |
| 2025-06-24 | Gaslightwala Abizer | President & CEO | Open market purchase | 5,203 | $1.16 |
| 2025-06-23 | Gaslightwala Abizer | President & CEO | Open market purchase | 943 | $1.15 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 06:30 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-16 | 4 | 2026-08-18 | View on SEC.gov → |
| 2026-10-16 | 4 | 2026-08-18 | View on SEC.gov → |
| 2026-10-16 | 4 | 2026-08-18 | View on SEC.gov → |
| 2026-10-16 | 4 | 2026-08-18 | View on SEC.gov → |
| 2026-10-16 | 4 | 2026-08-18 | View on SEC.gov → |
| 2026-10-16 | 4 | 2026-08-18 | View on SEC.gov → |
| 2026-10-14 | 4 | 2026-10-12 | View on SEC.gov → |
| 2026-10-01 | 4 | 2026-09-29 | View on SEC.gov → |
| 2026-10-01 | 8-K | 2026-09-29 | View on SEC.gov → |
| 2026-08-19 | 4 | 2026-08-17 | View on SEC.gov → |
| 2026-08-13 | 8-K | 2026-08-13 | View on SEC.gov → |
| 2026-08-13 | 10-Q | 2026-06-30 | View on SEC.gov → |
Recent news
Headlines about AKTX (Akari Therapeutics plc ADS). Links open the publisher — we don’t host full articles.
-
Akari Therapeutics(AKTX) Stock Options Chain | Quotes & News
Moomoo · 2026-10-20 -
AKTX Q2 2026 Earnings: Wider-Than-Expected Loss Weighs on Shares - Management Guidance Update
https://www.siam.in/ · 2026-10-19 -
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga · 2026-10-19 -
Why XCF Global Shares Are Trading Higher By Around 65%; Here Are 20 Stocks Moving Premarket
Benzinga · 2026-10-19 -
Discipline and Rules-Based Execution in AKTX Response
Stock Traders Daily · 2026-10-18 -
A director exercises warrants at $0.0004 per depositary share in Akari Therapeutics (AKTX).
Stock Titan · 2026-10-16 -
Unpaid director cash retainers are replaced by stock awards at Akari Therapeutics (AKTX).
Stock Titan · 2026-10-16 -
A director exercises warrants at $0.0004 per depositary share at Akari Therapeutics (AKTX).
Stock Titan · 2026-10-16
No headlines in this category right now — try “All”.